Regencell Bioscience Holdings Ltd (RGC)

Price$6.78Cached quoteAs of 2026-09-04 16:23 UTC

AI: Overvalued

Price checkThe market value is enormous beside the company’s cash, assets, and lack of revenue.

At the observed quote, about 495.5 million shares imply a stock-market value near $3.4 billion. Regencell reported no revenue through fiscal 2025 and only about $2.4 million of cash at June 2025. After the May 2026 financing, the prospectus estimated adjusted net tangible book value, meaning tangible assets minus liabilities, near $19.6 million, so the stock is valued at roughly 175 times that amount. With no earnings or sales to value, this asset check shows the price requires a very large future commercial payoff.

Big pictureLosses improved last year, but the business still has no proven source of recurring cash.

Fiscal 2025 operating cash use improved to $3.11 million from $4.00 million, while net loss was about $3.58 million. That improvement did not last: for the six months ended December 2025, net loss widened to $5.32 million from $1.85 million a year earlier. Management attributed much of the increase to about $2.3 million of investigation-related professional fees and higher stock-linked employee compensation. This is not mainly an economic-cycle story; cash durability depends on research progress, legal costs, and continued access to financing.

Business strengthThe May financing strengthened liquidity, but future share issuance remains a major ownership risk.

At June 2025, current assets were about $4.9 million versus $0.66 million of current liabilities, and cash exceeded debt by about $1.87 million. The May 2026 registered deal then added an estimated $18.4 million of net proceeds while issuing only 985,222 shares, roughly 0.2% of the prior share count. However, a March filing created a program allowing up to $500 million of additional share sales into the market. Heavy use could cause substantial dilution. The supplied financial history also shows no dividends or share buybacks.

What could change the storyClear trial progress, regulatory approval, or real sales could justify more of today’s valuation.

The clearest bull case is successful development and approval of Regencell’s standardized formulas, followed by meaningful recurring sales. The company owns exclusive rights to the practitioner’s formulas, but its May prospectus said the second efficacy trial began in 2021, produced an interim report in 2023, and no additional efficacy trials had been conducted since. The bear case is that commercialization stays distant while legal costs and financing continue. Independent controlled evidence, a defined approval path, and material product revenue are the concrete milestones needed to support a multibillion-dollar valuation.

AI: News

Justice Department trading probeThe Justice Department probe raised legal costs and triggered an immediate confidence shock.

On October 31, 2025, Regencell disclosed that the U.S. Department of Justice had subpoenaed documents and communications concerning trading in its shares and other operational, financial, and accounting matters. The company said the outcome was uncertain and warned of significant legal costs and possible penalties or settlements. Bloomberg reported the probe the same day; shares fell about 19% on the next trading day. This directly increased legal, governance, and financing risk.

First-half loss surgeFirst-half losses surged as investigation costs and stock compensation consumed much more cash.

On May 8, 2026, Regencell reported a $5.32 million net loss for the six months ended December 2025, up from $1.85 million a year earlier, while cash remained around $2.4 million. General and administrative expense jumped because professional fees tied to investigation matters increased by about $2.3 million and compensation linked to company stock rose sharply. The filing showed that legal and governance issues were already consuming resources that otherwise could support research.

Capital raise closedMay financing greatly improved liquidity with very little immediate share dilution.

On May 22, 2026, Regencell closed a registered direct offering of 985,222 shares for about $20 million of gross proceeds; the prospectus estimated about $18.4 million net after fees and expenses. The new shares represented only about 0.2% of the previous outstanding count, so immediate dilution was small relative to the cash raised. The financing materially strengthened the company’s runway, although the current market quote is roughly two-thirds below the deal’s per-share level.

Insider lock-up expiredJuly lock-up expiry removed a temporary sale restriction on the dominant shareholder.

On July 27, 2026, a post-offering lock-up period ended. The May prospectus had restricted the chief executive from selling or otherwise disposing of shares for 65 days after closing and the placement agent for 60 days, subject to exceptions. Because the chief executive beneficially owned 88.6% of shares in the latest annual report, expiry removed a contractual restriction on a very large holder. Any effect on trading is uncertain because the reviewed sources do not show that he sold shares.

Loading local price history

Revenue

2022

2023

2024

Net income

2019

2020

2021

2022

2023

2024

2025

Free cash flow

2020

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019
Revenue	—	$0	$0	$0	—	—	—
Research & development	$948,289	$1.1M	$1.6M	$2.5M	$438,323	$386,230	$228,223
Operating expenses	$3.8M	$4.7M	$6.3M	$7.6M	$1.4M	$812,371	$390,990
Operating income	−$3.8M	−$4.7M	−$6.3M	−$7.6M	−$1.4M	−$812,371	−$390,990
EBITDA	−$3.4M	−$4.0M	−$5.5M	−$7.0M	−$1.4M	−$802,855	—
Net income	−$3.6M	−$4.3M	−$5.9M	−$7.4M	−$1.3M	−$812,371	−$390,990
Basic EPSper basic share	-$0.01	-$0.01	-$0.01	-$0.02	$0.00	$0.00	—
Diluted EPSper diluted share	-$0.01	-$0.01	-$0.01	-$0.02	-$0.00	-$0.00	—

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders

Top 20 reported holders of RGC
Holder	Shares held
AU YAT-GAI	437.9M
LO MARGARET HOOR HAN	604.05K
AU YAT-PUI	581.51K
GEODE CAPITAL MANAGEMENT, LLC	422.01K
Alyeska Investment Group, L.P.	416.26K
Legal & General Group Plc	128K
JANE STREET GROUP, LLC	98.35K
XTX Topco Ltd	60.06K
Amundi	47.16K
UBS Group AG	43.21K
Quadrature Capital Ltd	41.75K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	23.13K
Squarepoint Ops LLC	22.04K
FOX RUN MANAGEMENT, L.L.C.	20.69K
CIBC Asset Management Inc	15.29K
BANK OF AMERICA CORP /DE/	14.99K
TWO SIGMA INVESTMENTS, LP	14.41K
Vident Advisory, LLC	11.2K
MORGAN STANLEY	5.05K
BlackRock, Inc.	4.93K

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)0$0.00 disclosed value

No insider transactions transactions were reported in the stored SEC coverage.

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about RGC yet. Start the conversation.

Write the first post

Regencell Bioscience Holdings Ltd (RGC)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.